Skip to content

Clinical trials

Glucose Intolerance trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glucose Intolerance Phase: Not applicable Clear all

484 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20044
20055
20067
200711
200813
200914
201010
201121
201216
201314
201422
201517
201627
201727
201838
201932
202019
202131
202240
202320
202430
202535
202627

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed306
Unknown status61
Recruiting40
Active, not recruiting25
Not yet recruiting20
Terminated15
Withdrawn13
Enrolling by invitation3
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Maastricht University Medical Center17
Johns Hopkins University9
Clinical Nutrition Research Center, Illinois Institute of Technology8
Singapore Institute of Food and Biotechnology Innovation8
University of California, Los Angeles7
University of Michigan6
Emory University5
Pennington Biomedical Research Center5
The University of Hong Kong5
NYU Langone Health4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glucose Intolerance484
Obesity119
Diabetes Mellitus, Type 295
Insulin Resistance93
Diabetes Mellitus83
Prediabetic State69
Overweight50
Metabolic Syndrome38
Hypertension21
Hyperglycemia20

Trials

Showing 76 to 100 of 484. Each trial links to its page on Pharma Observatory.

384 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.